「co.jp2024年7月8日」の検索結果
298件：61～65件目を表示
-
医療用医薬品に関するよくあるご質問 | 医療関係者向製品情報（医療用医薬品） | 医療関係者のみなさま | 千寿製薬株式会社
アイファガン点眼液0.1％ アイベータ配合点眼液 アイラミド配合懸濁性点眼液 アジマイシン点眼液1％ カタリン点眼用0.005% カタリンK点眼用0.005% ガチフロ点眼液0.3% タリムス点眼液0.1％ ニフラン点眼液0.1% フルオロメトロン点眼液0.02％「センジュ」フルオロメトロン点眼液0.05％「センジュ」フルオロメトロン点眼液0.1％「センジュ」 ヒアルロン酸Na点眼
https://www.senju.co.jp/medical/faq/ -
Milestones in Our History | About Senju | SENJU Pharmaceutical
1947 Apri Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. July Injection Product for Neutropenia, "PANILTIN", sales launched 1949 Feb
https://www.senju.co.jp/english/about/history.html -
Over-The-Counter Medicines | Business Activities | About Senju | SENJU Pharmaceutical
From eye drops to contact lens preparations-Mytear eye solutions head a diverse line of trusted products Building on a reputation for excellence in ophthalmological drugs, Senju Pharmaceutical has cul
https://www.senju.co.jp/english/about/business/otc.html -
千寿製薬株式会社
新闻 2025年12月22日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel
https://www.senju.co.jp/chinese/ -
Production | About Senju | SENJU Pharmaceutical
Trusted pharmaceutical products are created using the latest and best equipment in the environment with rich humanity. As ophthalmic solutions are required to meet the same quality standards as inject
https://www.senju.co.jp/english/about/production.html